1. Serum AST and ALT levels decreased significantly.2. Plasma markers of hepatic fibrosis were significantly reduced.3. Lipid profiles, renal function, serum electrolytes, plasma renin activities, serum Ang II levels, and HOMA-IR were unchanged.4. The degree of lobular steatosis was unaffected by the losartan treatment. The gene discussed is REN; the disease is steatosis.